24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108101
Title:
24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura.
Authors:
Anderson, Heather; Hasleton, Philip S; Michie, A B; Johnson, Richard J; Thatcher, Nick
Abstract:
Thirteen patients with malignant mesothelioma of the pleura have been treated with 24-hour cyclophosphamide infusion (2.5 g/m2) therapy. There were no complete responders. Three patients (23%) had a partial response, and a further three patients who did not fulfil the criteria for objective response, had subjective benefit from therapy with increase in performance status. The overall median survival from the onset of therapy was 6 months (range 2-19 months). High dose cyclophosphamide offers no advantage over standard dose therapy.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, Manchester.
Citation:
24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura. 1988, 82 (1):64-9 Br J Dis Chest
Journal:
British Journal of Diseases of the Chest
Issue Date:
Jan-1988
URI:
http://hdl.handle.net/10541/108101
DOI:
10.1016/0007-0971(88)90009-5
PubMed ID:
3166920
Language:
en
ISSN:
0007-0971
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorHasleton, Philip Sen
dc.contributor.authorMichie, A Ben
dc.contributor.authorJohnson, Richard Jen
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-07-21T15:17:53Z-
dc.date.available2010-07-21T15:17:53Z-
dc.date.issued1988-01-
dc.identifier.citation24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura. 1988, 82 (1):64-9 Br J Dis Chesten
dc.identifier.issn0007-0971-
dc.identifier.pmid3166920-
dc.identifier.doi10.1016/0007-0971(88)90009-5-
dc.identifier.urihttp://hdl.handle.net/10541/108101-
dc.description.abstractThirteen patients with malignant mesothelioma of the pleura have been treated with 24-hour cyclophosphamide infusion (2.5 g/m2) therapy. There were no complete responders. Three patients (23%) had a partial response, and a further three patients who did not fulfil the criteria for objective response, had subjective benefit from therapy with increase in performance status. The overall median survival from the onset of therapy was 6 months (range 2-19 months). High dose cyclophosphamide offers no advantage over standard dose therapy.en
dc.language.isoenen
dc.subjectPleural Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshCyclophosphamide-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInfusions, Parenteral-
dc.subject.meshLung-
dc.subject.meshMale-
dc.subject.meshMesothelioma-
dc.subject.meshMiddle Aged-
dc.subject.meshPleural Neoplasms-
dc.title24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura.en
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester.en
dc.identifier.journalBritish Journal of Diseases of the Chesten

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.